企業プロフィール
Coherus BioSciences, Inc. 株価・ニュース・カタリスト
- ティッカー:
- CHRS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.15 USD (-4.17%)
終値
最終更新: 2026年8月17日
234M USD
時価総額
株価変動の要因
The latest monitored company update is “Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights.” The corresponding closing-price reaction is not yet available.
企業概要
Immuno-Oncology Portfolio
Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.
Casdozokitug
Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.
Tagmokitug
Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.
今後のカタリスト
- Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026.
- Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026.
- First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026.
- Initial tagmokitug combination data in late-line colorectal cancer in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。